Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy

Penghu Han1, Shuzheng Chu2, Jing Shen1

  • 1Department of Gastroenterology, Qilu Hospital of Shandong University, Advanced Medical Research Institute, Shandong University, Jinan 250012, China.

Cell Metabolism
|October 25, 2025
PubMed

Insights

Quercetin metabolite DOPAC enhances anti-tumor immunity by boosting CD8+ T cell function. This microbial metabolite shows promise for cancer immunotherapy, particularly when combined with immune checkpoint blockade.

Area of Science:

  • Immunology
  • Oncology
  • Microbiology

Background:

  • Quercetin, a dietary flavonol, has potential in cancer prevention.
  • The impact of quercetin on the tumor microenvironment's immune cells is not fully understood.

Purpose of the Study:

  • To identify quercetin metabolites mediating anti-tumor effects.
  • To elucidate the mechanism by which these metabolites affect CD8+ T cells.
  • To explore the therapeutic potential of these metabolites in cancer immunotherapy.

Main Methods:

  • Identification of quercetin microbial metabolites.
  • In vitro assays to assess metabolite binding to KEAP1 and NRF2 interaction.
  • Analysis of NRF2-mediated gene expression in CD8+ T cells.
  • Assessment of CD8+ T cell function and mitochondrial health.
  • In vivo tumor models evaluating DOPAC efficacy alone and with immune checkpoint blockade.

Main Results:

  • 3,4-dihydroxyphenylacetic acid (DOPAC), a quercetin metabolite, mediates anti-tumor effects dependent on CD8+ T cells.
  • DOPAC binds KEAP1, preventing NRF2 degradation in CD8+ T cells.
  • Elevated NRF2 enhances BCL2-interacting protein 3, promoting mitophagy and improving CD8+ T cell fitness.
  • DOPAC synergizes with immune checkpoint blockade to inhibit tumor growth.

Conclusions:

  • Microbial metabolism of dietary nutrients plays a key role in anti-tumor immunity.
  • DOPAC enhances CD8+ T cell function and anti-tumor responses.
  • DOPAC is a promising candidate for cancer immunotherapy, especially in combination therapies.